ClinicalTrials.gg
CompletedNCT04980495ADAPT NXTUpdated May 27, 2026Results posted

An Open-label Study to Investigate the Clinical Efficacy of Different Dosing Regimens of Efgartigimod IV in Patients With Generalized Myasthenia Gravis

A Phase 3 interventional study of Efgartigimod IV in Generalized Myasthenia Gravis, MG - Myasthenia Gravis and gMG, sponsored by argenx. Completed at 39 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-27.

Sponsored by argenx · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
69
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing efgartigimod alfa in Myasthenia Gravis — 11 open to participants now, 14 under way, 7 of them phase 3. efgartigimod alfa · Myasthenia Gravis.

Enrollment
8th of 20
69 · median 55
Started
2021
with 3 others
Phase 3
10 of 20
3 open now
Registered
7th of 20
by date
Lead sponsor
12 of 20
argenx

Among the 20 studies testing efgartigimod alfa in Myasthenia Gravis, this one is the 8th largest by enrollment, is one of 4 that started in 2021, is one of 10 in phase 3, and was the 7th registered.

Myasthenia Gravis

331 studies on the registry are indexed under Myasthenia Gravis; 145 are open to participants now.

Browse Myasthenia Gravis studies →

Open to participants now

11 of the 20 studies testing efgartigimod alfa in Myasthenia Gravis are open now, in 12 countries. Recruiting first, the newest first:

6 more — sign in →

By country, each count listing its studies:

All 11 open studies →

About efgartigimod alfa

efgartigimod alfa: first FDA approval 2021 (VYVGART), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 104 Myasthenia Gravis studies recruiting now, 64 (62%) set no upper age limit and 23 (22%) stop at 75 or younger; 16 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing efgartigimod alfa in Myasthenia Gravis, or all of them as a file.
02

Study summary

The purpose of this open-label study is to investigate the efficacy, safety, and tolerability of a continuous regimen of efgartigimod compared with a cyclic regimen in participants with Generalized Myasthenia Gravis (gMG).

Participants will receive efgartigimod throughout the study. The participants will be randomized to the continuous regimen arm or to the cyclic regimen arm. The study consists of a part A (regimen comparison period) where participants will continue the treatment based on the treatment regimen arm they were assigned at randomization. Following part A, participants will enter part B (extension period) where all participants will receive efgartigimod in the continuous regimen. The study duration for participants is up to 138 weeks.

03

Conditions studied

  • Generalized Myasthenia Gravis
  • MG - Myasthenia Gravis
  • gMG

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 18 years of age, at the time of signing the .
  • Diagnosed with Generalized Myasthenia Gravis (gMG) with confirmed documentation and supported by a physical exam and confirmed seropositivity for anti-acetylcholine receptor antibodies (AChR-Abs).
  • Meets the clinical criteria as defined by the Myasthenia Gravis Foundation of America (MGFA) class II, III, or IV

Exclusion criteria

Exclusion Criteria:

  • Any other condition that, in the opinion of the investigator, would interfere with an accurate assessment of the clinical symptoms of gMG and/or put the participant at undue risk
  • A thymectomy within 3 months of screening
  • Use of the following prior or concomitant therapies:

    1. intravenous immunoglobulin (IVIg) or subcutaneous immunoglobulin (SCIg) within 14 days of day 1
    2. Rituximab within 6 months of day 1
    3. Eculizumab within 1 month of day 1
    4. Other monoclonal antibodies (eg, adalimumab, tocilizumab, ixekizumab)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
69 participants (actual)

Study arms

  • Experimental
    Efgartigimod IV - continuous regimen

    Participants receiving efgartigimod IV on a continuous regimen

    Biological: Efgartigimod IV

  • Experimental
    Efgartigimod IV - cyclic regimen

    Participants receiving efgartigimod IV on a cyclic regimen

    Biological: Efgartigimod IV

Interventions

06

What researchers measure

Primary outcomes

  1. Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 21 weeks

Secondary outcomes

  1. Incidence of AEs, SAEs and AESIs

    AE : adverse event; SAE: serious adverse event; AESI: adverse event of special interest

    Time frame: Up to 135 weeks

  2. Change From Baseline in the MG-ADL Total Score Over Time

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 126 weeks

  3. Normalized Area Under the Effect Curve (AUEC) of MG-ADL Total Score Improvement From Baseline

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 21 weeks

  4. Characterization of MG-ADL Total Score Change From Baseline

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 21 weeks

  5. Percentage of Participants Who Have a ≥ 2, 3, 4, or 5 Points Improvement in MG-ADL Total Score From Baseline

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 21 weeks

  6. Percentage of Time Participants Have a Change in MG-ADL Total Score of at Least 2 Points From Baseline During Week 4 Through Week 21

    The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: From week 4 to week 21

  7. Percentage of Participants Who Achieve MSE, Defined as a MG-ADL Total Score of 0 or 1

    MSE = minimal symptom expression; The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

    Time frame: Up to 21 weeks

07

Results

Posted May 27, 2026
Limitations and caveats
The results presented are based on the primary completion date, therefore only the results of part A are shown. Remaining results will be reported within a year of global study completion.

Participant flow

The study was conducted at 31 sites that enrolled participants with anti-acetylcholine receptor antibody (AChR-Ab) seropositive gMG in 11 countries. A total of 98 participants were screened of whom 69 were randomized and treated. The results presented are based on the primary completion date. Remaining results will be reported within a year of global study completion.

Participant flow — Overall Study
MilestoneEfgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous Regimen
Started1752
Completed part a1550
Completed1135
Not completed617
Withdrew: Adverse event23
Withdrew: Death01
Withdrew: Lack of efficacy12
Withdrew: Lost to follow-up10
Withdrew: Physician decision12
Withdrew: Pregnancy01
Withdrew: Requires prohibited medication02
Withdrew: Withdrawal by subject14
Withdrew: Other reasons02

Outcome measures

PrimaryMean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 21 weeks
Reported as:
Least squares mean · Score on a scale
Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm
Score on a scaleEfgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous Regimen
Mean of the Average MG-ADL Total Score Change From Baseline During the Visit of Week 1 Through Week 21 by Regimen Arm-5.13 (-6.499 to -3.767)-4.61 (-5.383 to -3.845)
SecondaryIncidence of AEs, SAEs and AESIs

AE : adverse event; SAE: serious adverse event; AESI: adverse event of special interest

Time frame:
Up to 135 weeks

Results for this outcome have not been posted.

SecondaryChange From Baseline in the MG-ADL Total Score Over Time

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 126 weeks

Results for this outcome have not been posted.

SecondaryNormalized Area Under the Effect Curve (AUEC) of MG-ADL Total Score Improvement From Baseline

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 21 weeks

Results for this outcome have not been posted.

SecondaryCharacterization of MG-ADL Total Score Change From Baseline

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 21 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Have a ≥ 2, 3, 4, or 5 Points Improvement in MG-ADL Total Score From Baseline

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 21 weeks

Results for this outcome have not been posted.

SecondaryPercentage of Time Participants Have a Change in MG-ADL Total Score of at Least 2 Points From Baseline During Week 4 Through Week 21

The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
From week 4 to week 21

Results for this outcome have not been posted.

SecondaryPercentage of Participants Who Achieve MSE, Defined as a MG-ADL Total Score of 0 or 1

MSE = minimal symptom expression; The MG-ADL (Myasthenia Gravis Activities of Daily Living) scale assesses MG symptoms and their effects on daily activities. The total score varies between 0 and 24, with higher total scores indicating more impairment.

Time frame:
Up to 21 weeks

Results for this outcome have not been posted.

Adverse events

Collected over Part A, up to week 21. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Efgartigimod IV - Cyclic Regimen0/17 (0%)1/17 (5.9%)16/17 (94.1%)
Efgartigimod IV - Continuous Regimen0/52 (0%)7/52 (13.5%)43/52 (82.7%)
Most frequent serious events
Most frequent serious events
EventEfgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous Regimen
COVID-19Infections and infestations1/170/52
MYASTHENIA GRAVISNervous system disorders1/172/52
MYASTHENIA GRAVIS CRISISNervous system disorders1/170/52
BRONCHITISInfections and infestations0/171/52
BACK PAINMusculoskeletal and connective tissue disorders0/171/52
TRANSIENT ISCHAEMIC ATTACKNervous system disorders0/171/52
DYSPNOEARespiratory, thoracic and mediastinal disorders0/171/52
RESPIRATORY SYNCYTIAL VIRUSInfections and infestations0/171/52
Most frequent other events
Showing 10 of 63
Most frequent other events
EventEfgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous Regimen
HEADACHENervous system disorders5/178/52
COVID-19Infections and infestations1/1711/52
INFLUENZAInfections and infestations2/173/52
NASOPHARYNGITISInfections and infestations2/171/52
UPPER RESPIRATORY TRACT INFECTIONInfections and infestations2/175/52
HYPERCHOLESTEROLAEMIAMetabolism and nutrition disorders2/172/52
ARTHRALGIAMusculoskeletal and connective tissue disorders2/171/52
MYALGIAMusculoskeletal and connective tissue disorders2/172/52
DIZZINESSNervous system disorders2/171/52
ALANINE AMINOTRANSFERASE INCREASEDInvestigations2/170/52

Baseline characteristics

Age, Continuous
Age, Continuous(Age (years))Efgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous RegimenTotal
Mean52.4 ± 16.1057.1 ± 16.4955.9 ± 16.40
Age, Customized
Age, Customized(Participants)Efgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous RegimenTotal
Age, category — 18 - 64 years123244
Age, category — >= 65 years52025
Sex: Female, Male
Sex: Female, Male(Participants)Efgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous RegimenTotal
Female93443
Male81826
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous RegimenTotal
Race — Asian011
Race — Black or African American202
Race — White145064
Race — Other101
Race — Unknown011
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Efgartigimod IV - Cyclic RegimenEfgartigimod IV - Continuous RegimenTotal
Ethnicity — Hispanic or Latino022
Ethnicity — Not Hispanic or Latino175067
08

Study locations

39 sites
  • Investigator Site 10 - US0010007
    Carlsbad, California 92011, United States
  • Investigator Site 7 - US0010001
    Orange, California 92868, United States
  • Investigator Site 9 - 0010006
    Boca Raton, Florida 33487, United States
  • Investigator Site 15 - US0010014
    Coral Springs, Florida 33067, United States
  • Investigator Site 16 - US0010009
    Augusta, Georgia 30910, United States
  • Investigator Site 8 - US0010003
    Chicago, Illinois 60611, United States
  • Investigator Site 6 - US0010008
    Meadows, Illinois 60008, United States
  • Investigator Site 12 - US0010004
    Kansas City, Kansas 66160, United States
  • Investigator Site 13 - US0010013
    Portland, Oregon 97239, United States
  • Investigator Site 17 - US0010012
    Philadelphia, Pennsylvania 19104, United States
  • Investigator Site 11 - US0010011
    Austin, Texas 78756, United States
  • Investigator Site 14 - US0010010
    Richmond, Virginia 23219, United States
  • Investigator Site 26 - AT0430002
    Innsbruck, 6020, Austria
  • Investigator Site 27 - AT0430001
    Vienna, 1090, Austria
  • Investigator Site 28 - BE0320001
    Leuven, 3000, Belgium
  • Investigator Site 29 - CA0019003
    London, N6A 5A5, Canada
  • Investigator site 37 - CA0019002
    Québec, H3A 2B4, Canada
  • Investigator Site 23 - FR0330005
    Bordeaux, 33604, France
  • Investigator Site 24 - FR0330004
    Lille, 59000, France
  • Investigator Site 20 - FR0330001
    Marseille, 13385, France
  • Investigator Site 25 - FR0330003
    Nice, 06001, France
  • Investigator site 38 - FR0330002
    Paris, 75013, France
  • Investigator Site 2 - GEO9950002
    Tbilisi, 0112, Georgia
  • Investigator Site 1 - GEO9950001
    Tbilisi, 0114, Georgia
  • Investigator Site 3 - GEO9950003
    Tbilisi, 0114, Georgia
  • Investigator Site 33 - DE0490004
    Berlin, 10117, Germany
  • Investigator Site 36 - DE0490002
    Bochum, 44791, Germany
  • Investigator Site 32 - DE0490001
    Essen, 45147, Germany
  • Investigator Site 34 - DE0490005
    Hanover, 30625, Germany
  • Investigator Site 31 - IT0390005
    Bologna, 40139, Italy
  • Investigator Site 30 - IT0390004
    Genova, 16132, Italy
  • Investigator Site 21 - IT0390002
    Milan, 20133, Italy
  • Investigator site 39 - IT0390006
    Pisa, 56126, Italy
  • Investigator Site 22 - IT0390001
    Roma, 00168, Italy
  • Investigator Site 35 - NL0310001
    Amsterdam, 1105, Netherlands
  • Investigator Site 5 - PL0480002
    Krakow, 31-426, Poland
  • Investigator Site 4 - PL0480001
    Lubin, 20-093, Poland
  • Investigator Site 18 - ES0340002
    Santiago de Compostela, A Coruña 15706, Spain
  • Investigator Site 19 - ES0340001
    Barcelona, 08041, Spain
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2021 to primary completion in Aug 2023, 20 months.

Results were first posted in May 2026, 2 years 9 months after primary completion. A results delay was requested in Feb 2024.

Of 43 industry-sponsored phase 3 interventional studies under Myasthenia Gravis, half reached primary completion within 27 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 39. This study's 20 months is below that.

Counting every sponsor, half of 52 studies reached it within 30 months; a quarter within 20 and three quarters within 43.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 19, 2021
First posted
Jul 28, 2021
StartActual
Dec 16, 2021
Primary completionActual
Aug 24, 2023
CompletionActual
Oct 6, 2025
Results delay requested
Feb 20, 2024
Results first posted
May 27, 2026
Last update
May 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 27, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04980495
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jul 28, 2021
Start date
Dec 16, 2021
Primary completion
Aug 24, 2023
Completion
Oct 6, 2025
Results posted
May 27, 2026
Last update
May 27, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efgartigimod alfa

Start the discussion